CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 16 enrolled
Drug / intervention
BI 425809 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03988803
NCT03988803Phase 1Completed

A Study to Investigate the Effects of Memantine on the Pharmacokinetics of BI 425809 and Vice Versa in Healthy Male and Female Subjects (Non-randomized, Single-arm, Open-label, Three-period, One Fixed Sequence Cross-over Study)

Boehringer Ingelheim·interventional·Posted Jun 17, 2019·Updated Apr 13, 2021

In Brief

A Phase 1 clinical trial evaluating BI 425809 and Memantine for Healthy. Completed, enrolled 16 participants across 1 site.

Detailed Summary

Investigate the effect of steady state exposures of memantine on the steady-state pharmacokinetics of BI 425809 and vice versa in healthy subjects.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesGermany
Collaborators--

Timeline

Phase 1CompletedFinished
2020202120222023202420252026
First PostedJun 17, 2019
Enrollment StartJul 17, 2019
Primary CompletionOct 30, 2019
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 7.0 years ago

Interventions

BI 425809drug

Film coated tablet

Memantinedrug

Film coated tablet